Aluminium hydroxide + Magnesium hydroxide


Generic Medicine Info
Indications and Dosage
Oral
Gastrointestinal hyperacidity
Adult: Available preparations:
Aluminium hydroxide 200 mg and magnesium hydroxide 200 mg per 5 mL susp
Aluminium hydroxide 220 mg and magnesium hydroxide 195 mg per 5 mL susp
Aluminium hydroxide 175 mg and magnesium hydroxide 200 mg per 5 mL susp
10-20 mL 4 times daily, given 20 minutes to 1 hour after meals and at bedtime or as required. Max: 80 mL per 24 hours.

Aluminium hydroxide 160 mg and magnesium hydroxide 105 mg chewable tablet
Chew 2-4 tab 4 times a day or as required. Max: 16 tab per 24 hours.
Child: ≥12 years Same as adult dose.
Contraindications
Severe abdominal pain and/or possibility of bowel obstruction. Severely debilitated patients. Renal failure.
Special Precautions
Patient with porphyria (and undergoing haemodialysis), diarrhoea or constipation. Renal impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Hypophosphataemia (prolonged use), diarrhoea or constipation.
Gastrointestinal disorders: Abdominal pain.
Injury, poisoning and procedural complications: Hyperaluminaemia.
Metabolism and nutrition disorders: Hypermagnesaemia (prolonged use).
Overdosage
Symptoms: Abdominal pain, diarrhoea, vomiting. Large doses may aggravate intestinal obstruction and ileus in patients at risk. Management: Correct fluid deficiency if necessary. Acute overdose may be treated by administration of calcium gluconate IV, rehydration, and forced diuresis.
Drug Interactions
Interferes with the absorption of ciprofloxacin, chloroquine, hydroxychloroquine, chlorpromazine, cefdinir, cefpodoxime, ketoconazole, levothyroxine, rifampicin, rosuvastatin, tetracyclines, vitamins. May reduce the effect of polystyrene sulphonate. Decreased serum concentration of velpatasvir. Increased absorption with citrate-containing preparations. May decrease absorption of Fe salts.
Magnesium hydroxide: Increases the excretion of salicylates.
Action
Description:
Mechanism of Action: Aluminium hydroxide is a slow-acting antacid that binds phosphate in the gastrointestinal tract to form insoluble complexes and reduces phosphate absorption. It also acts as an astringent and may cause diarrhoea.
Magnesium hydroxide is a fast-acting antacid which counteracts the constipating effect of aluminium hydroxide.
Pharmacokinetics:
Metabolism: Aluminium hydroxide: Slowly converted to aluminium chloride in the stomach.
Excretion: Via urine.
Chemical Structure

Chemical Structure Image
Aluminium hydroxide

Source: National Center for Biotechnology Information. PubChem Database. Aluminum hydroxide, CID=10176082, https://pubchem.ncbi.nlm.nih.gov/compound/Aluminum-hydroxide (accessed on Jan. 20, 2020)


Chemical Structure Image
Magnesium hydroxide

Source: National Center for Biotechnology Information. PubChem Database. Milk of magnesia, CID=73981, https://pubchem.ncbi.nlm.nih.gov/compound/Milk-of-magnesia (accessed on Jan. 20, 2020)

Storage
Store between 20-25°C.
MIMS Class
Antacids, Antireflux Agents & Antiulcerants
References
Anon. Aluminium Hydroxide and Magnesium Hydroxide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/02/2018 .

Buckingham R (ed). Aluminium Hydroxide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/02/2018.

ConRx-AR Tablet, Chewable (Eagle Distributors, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/02/2018 .

Mag-Al Liquid (Pharmaceutical Associates, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/02/2018 .

Superdrug Indigestion Relief Liquid (Chemidex Pharma Limited). MHRA. https://products.mhra.gov.uk/. Accessed 05/02/2018 .

Disclaimer: This information is independently developed by MIMS based on Aluminium hydroxide + Magnesium hydroxide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
  • Antasida Doen Mersifarma
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in